Related references
Note: Only part of the references are listed.AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance
Giuseppe Avvisati et al.
BLOOD (2011)
Modern Approaches to Treating Acute Promyelocytic Leukemia
Miguel A. Sanz et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience
Lionel Ades et al.
BLOOD (2010)
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710
Bayard L. Powell et al.
BLOOD (2010)
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Kenneth F. Schulz et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
The race and dose of chemotherapy should be considered for optimizing maintenance therapy for acute promyelocytic leukemia
Sumimasa Nagai et al.
LEUKEMIA RESEARCH (2009)
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin
Javier de la Serna et al.
BLOOD (2008)
Acute promyelocytic leukemia: from highly fatal to highly curable
Zhen-Yi Wang et al.
BLOOD (2008)
A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARα transcript after consolidation therapy:: The Japan Adult Leukemia Study Group (JALSG) APL97 study
Norio Asou et al.
BLOOD (2007)
Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL)
V Gupta et al.
LEUKEMIA RESEARCH (2005)
All-trans retinoic acid/AS2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia
ZX Shen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy:: a multicenter study by the PETHEMA group
MA Sanz et al.
BLOOD (2004)
Share Paper
